Stockscreener 앱 받기
97.74
1.02%
-1.01
전일 마감가:
$98.75
열려 있는:
$98.75
하루 거래량:
778.88K
Relative Volume:
0.55
시가총액:
$8.49B
수익:
$688.00K
순이익/손실:
$-168.74M
주가수익비율:
-41.46
EPS:
-2.3577
순현금흐름:
$-185.87M
1주 성능:
+12.82%
1개월 성능:
+30.18%
6개월 성능:
+219.31%
1년 성능:
+512.41%
1일 변동 폭
$94.13
$99.34
1주일 범위
$86.60
$99.34
52주 변동 폭
$14.51
$102.06
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
97.74 | 8.49B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Raymond James | Strong Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) Study result Summary - Quartr
Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre gives six new hires equity awards worth 58,843 options - Stock Titan
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE) - Seeking Alpha
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - TradingView
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design - Yahoo Finance
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts - Yahoo Finance
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing - Moomoo
Spyre Therapeutics, Inc.(NasdaqGS:SYRE) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 2500 Value Benchmark - marketscreener.com
Spyre Therapeutics Files for Offering up to a - Moomoo
Form S-3ASR Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com India
Form 4 Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock - Investing.com UK
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock By Investing.com - Investing.com South Africa
Spyre Therapeutics Chief Financial Officer Sold Shares Worth Over $1.3M - TradingView
Spyre Therapeutics (SYRE) CFO sells 15,000 shares after option exercise - Stock Titan
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Burrows Scott L - Moomoo
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
Spyre Therapeutics Files For Mixed Shelf Size Not DisclosedFiling - TradingView
Spyre Therapeutics files prospectus for mixed shelf - scanx.trade
Spyre Therapeutics (NASDAQ: SYRE) launches $500M at‑the‑market program - Stock Titan
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset - Seeking Alpha
Enterprise value to EBITDA forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics, Inc Actuals & Estimates (NASDAQ:SYRE) - TradingView
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):